Anti-tuberculosis drug
- 總結
- PPI-benzimidazole analogues for the treatment of multidrug-resistant tuberculosis.
- 技術優勢
- Active against multidrug-resistant tuberculosis
Small molecule
Tested in-vitro and in-vivo
SAR data available
- 技術應用
- new drug to treat Mtb infections.
- 詳細技術說明
- he inventors were able to demonstrate that lansoprazole and derivatives thereof exhibit growth inhibiting properties against intracellular Mtb. In particular, it has been proven that the reduced form lansoprazole sulfide is the active moiety. Yet, lansoprazole is not metabolized in a sufficient amount to serve as a prodrug. Thus, the inventors propose lansoprazole sulfide (LPZS) as a new drug to treat Mtb infections.
- 合作類型
- Licensing
- 申請日期
- 26/01/2016 00:00:00
- 申請號碼
- EP20160701631 20160126
- 分類
- - international:
A61K31/4439; A61K45/06; A61P31/06
- cooperative:
default
A61K31/4439; A61K45/06; A61P31/06; C07D401/12; A61K2300/00
C-sets
A61K31/4439, A61K2300/00
- 其他
- Patent application
- ID號碼
- 5126
- 國家/地區
- 德國
欲了解更多信息，請點擊 這裡
